Lansoprazol 1 A Pharma

Lansoprazole, the active ingredient in Lansoprazol 1 A Pharma, is a proton pump inhibitor presented as an oral formulation for oral use. It reduces gastric acid production and is indicated for conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens, and Zollinger‑Ellison syndrome.

GNH USA supplies Lansoprazol 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): lowers esophageal acid exposure and promotes mucosal healing. - Peptic ulcer disease: facilitates ulcer healing by suppressing gastric acid secretion. - Helicobacter pylori eradication regimens: enhances antibiotic efficacy by creating a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually self‑limiting. - Nausea or abdominal discomfort: occasional upset stomach. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Acute interstitial nephritis: kidney inflammation presenting with rash and fever. - Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmias. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Before prescribing Lansoprazole, consider the following precautions. - Assess renal function: adjust therapy if severe impairment exists. - Evaluate for osteoporosis risk: long‑term use may affect calcium absorption. - Monitor for infections: reduced gastric acidity can increase susceptibility to gastrointestinal infections. - Review concomitant medications: potential for drug‑drug interactions. - Store at ambient temperature: keep below 25°C, protect from moisture and keep in the original packaging.

Lansoprazole can influence the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption; avoid concurrent use. - Atazanavir: markedly decreased antiviral levels; contraindicated.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in anticoagulant effect; monitor INR. - Digoxin: modest rise in serum concentration; assess for toxicity. - Methotrexate (high dose): reduced clearance; monitor renal function and drug levels.